甲胎蛋白阳性胃癌的分子机制与诊疗现状
作者: |
1陆泳言,
1姜文凯,
2李硕,
1,3易剑锋
1 兰州大学第一临床医学院,兰州 730000 2 兰州大学第二临床医学院,兰州 730000 3 甘肃中医药大学第一临床医学院,兰州 730000 |
通讯: |
易剑锋
Email: yijf02@163.com |
DOI: | 10.3978/j.issn.2095-6959.2022.09.030 |
基金: | 甘肃中医药大学科学研究与创新基金(2020KCZD-6);甘肃省高等学校创新基金(2021B-161)。 |
摘要
Mechanisms, clinical diagnosis and treatment of alpha-fetoprotein-producing gastric cancer: The research status
CorrespondingAuthor: YI Jianfeng Email: yijf02@163.com
DOI: 10.3978/j.issn.2095-6959.2022.09.030
Foundation: This work was supported by the Science and Innovation Fund Project of Gansu University of Traditional Chinese Medicine (2020KCZD-6), and Gansu Province Higher Education Innovation Fund Project (2021B-161), China.
Abstract
Alpha-fetoprotein-producing gastric cancer (AFPGC) is a special type of gastric cancer with unique molecular mechanism and clinicopathological features compared with conventional gastric cancer. It has already attracted the attention of clinicians in recent years due to its high metastasis rate, poor prognosis and frequent misdiagnosis. In recent years, the overexpression of molecules such as vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (HER2), cellular-mesenchymal epithelial transition factor (c-Met), spalt-like transcription factor 4 (SALL4) and microRNA (miRNA) in AFPGC could reveal the correlation between relevant signaling pathways and carcinogenic molecule and this kind of gastric cancer in some way. Molecular targeting drugs such as chemotherapeutic drugs, apatinib and trastuzumab have also shown efficacy against AFPGC.